Related Experiment Video
Updated: Aug 10, 2026
06:16
Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model
Published on: April 19, 2024
From the design to the clinical application of thromboxane modulators
Jean-Michel Dogné1, Julien Hanson, Xavier de Leval
1Natural and Synthetic Drug Research Centre, Medicinal Chemistry, University of Liège, Belgium. Jean-Michel.Dogne@ulg.ac.be
Current Pharmaceutical Design
|March 15, 2006
Summary
Thromboxane A(2) (TXA(2)) plays a crucial role in cardiovascular and inflammatory diseases. This review explores TXA(2) modulators, their therapeutic applications, and future drug design perspectives for various pathologies.
Area of Science:
- Biochemistry
- Pharmacology
- Pathophysiology
Background:
- Arachidonic acid (AA) metabolites, particularly thromboxane A(2) (TXA(2)), are central to cardiovascular, pulmonary, inflammatory, and thromboembolic diseases.
- TXA(2), produced from AA via prostaglandin endoperoxide H(2) (PGH(2)), potently induces platelet aggregation, vasoconstriction, and bronchoconstriction.
- Its involvement in major pathophysiological conditions has driven the development of TXA(2) receptor antagonists and thromboxane synthase inhibitors since the 1980s.
Purpose of the Study:
- To review the physiological roles of TXA(2), thromboxane synthase, and TXA(2) receptors.
- To describe existing classes of TXA(2) modulators, detailing their advantages and disadvantages.
- To present recent studies on TXA(2) modulators in key pathologies and explore future therapeutic applications.
Main Methods:
- Literature review of physiological properties of TXA(2) and its modulators.
- Systematic review of recent studies on TXA(2) modulators in myocardial infarction, atherosclerosis, diabetes, pulmonary embolism, septic shock, preeclampsia, and asthma.
- Analysis of current perspectives in drug design and future therapeutic applications of TXA(2) modulators.
Main Results:
- TXA(2) is a significant mediator in numerous diseases, necessitating therapeutic intervention.
- Various TXA(2) modulators, including receptor antagonists and synthase inhibitors, have been developed and evaluated.
- Recent studies highlight the potential of these modulators in treating diverse conditions, with ongoing research into novel applications.
Conclusions:
- TXA(2) modulators represent a critical therapeutic strategy for a range of diseases.
- Continued research into TXA(2) modulators holds promise for improved treatment of cardiovascular, inflammatory, and thromboembolic disorders.
- Future drug design and therapeutic applications may extend to oncology, including cancer, metastasis, and angiogenesis.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.